Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection
Open Access
- 19 April 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 59 (6) , 1047-1056
- https://doi.org/10.1093/jac/dkm082
Abstract
Transmission of drug-resistant HIV-1 variants from antiretroviral treatment-experienced persons has been documented to occur through multiple routes, including sexual intercourse, intravenous drug use and vertically from mother to child. Newly infected persons with transmitted drug resistance (TDR) also act as a source for the onward transmission of resistant variants. Rates of virological suppression and behavioural patterns of treated populations and the relative fitness of drug-resistant variants are important determinants of the prevalence of TDR. Current estimates indicate that the prevalence is highest in regions and populations with long-established use of antiretroviral therapy. Limited data suggest that the incidence of TDR is rising in developing countries where access to therapy is increasing. There are methodological variations between studies, however, including those relative to the selection of the study population and the resistance interpretation system, which can skew prevalence estimates. TDR has important implications for the successful management of antiretroviral therapy. Routine resistance testing of drug-naive persons has been widely adopted in affluent countries and shown to effectively guide the selection of first-line regimens. Genotypic resistance tests offer a practical approach for detecting TDR. However, routine methods can only detect resistant mutants within the dominant quasispecies and fail to detect low-frequency resistant variants, which may become important once selective drug pressure is introduced. More sensitive testing methods are being evaluated but remain research tools at present. In addition, factors such as superinfection and possible differences in resistance patterns between plasma and cellular reservoirs and between anatomical compartments should be considered when evaluating TDR.Keywords
This publication has 72 references indexed in Scilit:
- Clinical Utility of HIV Standard Genotyping among Antiretroviral-Naive Individuals with Unknown Duration of InfectionClinical Infectious Diseases, 2007
- HIV-1 protease and reverse transcriptase mutations for drug resistance surveillanceAIDS, 2007
- Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south BrazilVirus Research, 2006
- The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 SubtypesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Short Communication:Low Prevalence of Genotypic Drug Resistance Mutations among Antiretroviral-Naive HIV Type 1 Patients in MalaysiaAIDS Research and Human Retroviruses, 2006
- Genotypic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 in Antiretroviral Drug-Naive Nigerian PatientsAIDS Research and Human Retroviruses, 2006
- Antiretroviral Recommendations May Influence the Rate of Transmission of Drug‐Resistant HIV Type 1Clinical Infectious Diseases, 2005
- HIV-1 Drug Resistance in Newly Infected IndividualsJAMA, 1999
- Transmission of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Variants Following Deliberate Injection of Blood from a Patient with AIDS: Characteristics and Natural History of the VirusClinical Infectious Diseases, 1995
- Primary Infection with Zidovudine-Resistant Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1993